Drugs / Clostridium butyricum
Clostridium butyricum
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02254629 | Jul 2014 → Aug 2015 | irritable bowel syndrome | Shandong University | Completed | No outcome recorded |
| Phase 1 | NCT02169388 | Jun → Oct 2014 | chemotherapy-induced toxicity, colorectal cancer, nutritional disorder | Shandong University | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07474064 | Mar 2026 → Mar 2031 expected | urinary bladder carcinoma | chenxu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06696742 | Feb 2024 → Feb 2029 expected | bladder transitional cell carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05914389 | Aug 2023 → Aug 2025 overdue | colonic neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 47 trials · 1 missed | ||||||
| Phase 4 | NCT07167342 | May 2026 → Apr 2030 expected | colorectal adenoma | The Affiliated Hospital of Qingdao University | Recruiting | No outcome recorded |
| Phase 4 | NCT07152886 | Oct 2025 → Oct 2027 expected | chemotherapy-induced toxicity, colorectal cancer | The Affiliated Hospital of Qingdao University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07182890 | Sep 2025 → Oct 2026 expected | anxiety, depressive disorder, dyspepsia | Xijing Hospital of Digestive Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT05237115 | May → Dec 2020 | dyspepsia, gastritis, peptic ulcer disease | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT05687409 | Nov 2019 → May 2021 | cirrhosis of liver, metagonimiasis | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT03857425 | Mar → Aug 2019 | Helicobacter pylori infectious disease, dyspepsia, gastritis | Xijing Hospital of Digestive Diseases | Completed | Missed primary |
| Phase 4 | NCT02614963 | Dec 2015 → Jul 2016 | — | Shandong University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06998823 | Mar 2024 → Oct 2025 overdue | cancer-related condition | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00947336 Comparator | Apr 2005 → Apr 2008 | cirrhosis of liver | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-02-28 | Osel, Inc. | Results City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May
Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer oselinc.com ↗
To our knowledge, this is the first randomized clinical trial to demonstrate that a live bacterial product can modulate the gastrointestinal microbiome and enhance immunotherapy response in cancer patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-02-28 | Osel, Inc. | City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer oselinc.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium butyricum | “A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).” NCT05687409 ↗13“synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores)” NCT00947336 ↗ “This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment.” PMID 33157939 ↗ Nov 2020 “Clostridium butyricum is a spore-forming bacillus named for its capacity to produce high amounts of butyric acid and is found in soil.” NCT06998823 ↗ “oral probiotics (Clostridium butyricum) work to improve the efficacy” NCT07474064 ↗ “（ clostridium butyricum）” NCT02169388 ↗ |
| Known as | C butyricum | “This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment.” PMID 33157939 ↗ Nov 2020 |
| Known as | MIYA-BM | “Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea,...” NCT06998823 ↗ |
| Known as | MIYAIRI 588 strain | “Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea,...” NCT06998823 ↗ |
| Action | Inhibit | “CONCLUSION: C butyricum and B coagulans may effectively inhibit H pylori to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.” PMID 33157939 ↗ Nov 2020 |
| Modality | Other / unclassified | “Probiotic Clostridium Butyricum” NCT02254629 ↗ |
| Route | Oral | “Participants orally administered the contents three times daily after meals” NCT05687409 ↗ |